Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Average Price Target from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have received an average rating of "Buy" from the ten analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $65.00.

Several analysts have issued reports on VERA shares. HC Wainwright reissued a "buy" rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wedbush reduced their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald reduced their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th.

Vera Therapeutics Trading Up 3.8%

Vera Therapeutics stock traded up $0.79 during mid-day trading on Friday, hitting $21.65. 1,804,520 shares of the company's stock were exchanged, compared to its average volume of 962,139. The firm has a market capitalization of $1.38 billion, a P/E ratio of -7.22 and a beta of 1.13. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a quick ratio of 27.68, a current ratio of 27.68 and a debt-to-equity ratio of 0.10. The company's 50 day simple moving average is $22.49 and its 200-day simple moving average is $29.32.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the business earned ($0.56) earnings per share. On average, equities analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current year.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VERA. Quarry LP boosted its stake in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $60,000 after buying an additional 500 shares during the period. Huntington National Bank bought a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $26,000. Summit Investment Advisors Inc. boosted its stake in shares of Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after buying an additional 639 shares during the period. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $34,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after buying an additional 800 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.